Abstract
Stent-based local drug release at the site of vascular injury via a polymer-coated drug-eluting stent (DES) is an attractive therapeutic approach to prevent in-stent restenosis. Estrogens were discussed as active agents for second generation DES due to their differential effects on human coronary artery endothelial (HCAEC) and smooth muscle cells (HCASMC). We have tested the effects of genistein and 17β-estradiol on HCAEC and HCASMC in vitro, and developed genistein DES prototypes with a biodegradable poly(L-lactide) (PLLA) matrix which were tested in vitro and in vivo. In vitro, genistein showed a concentration dependent inhibition of HCASMC proliferation, whereas 17β-estradiol was less effective. Proliferation of HCAEC was markedly stimulated by genistein, but barely stimulated by 17β-estradiol. The genistein release profile showed an initial burst and subsequent steady release over more than 3 months. After stent expansion, the PLLA/genistein coating exhibited structural integrity and a smooth surface. In vivo, the PLLA/genistein DES showed complete re-endothelialization after 4 weeks and a reduction in stenosis diameter, and reduced stenosis area in comparison to the PLLA coated control group (QCA data). In contrast, the histomorphometrical evaluation showed no significant differences regarding coronary stenosis and neointimal area between both groups, and thus has not confirmed the QCA data. The conducted in vitro and in vivo studies indicate the potential of PLLA/genistein DES for enhanced re-endothelialization. However, for the prevention of the restenosis process via a chain of different immunological and biochemical reactions combined DES concepts with genistein and antiproliferative drugs, such as sirolimus are essential.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kukreja N, Onuma Y, Daemen J, Serruys PW. The future of drugeluting stents. Pharmacol Res. 2008 Mar;57(3):171–80.
Geraldes P, Geoffroy P, Cloutier I, Sirois MG et al. Local Delivery of 17-Beta-Estradiol Modulates Collagen Content in Coronary Porcine Arteries after PTCA and Stent Implantation. J Vasc Res. 2008 May 2;45(6):503–511.
Abizaid A, Chaves AJ, Leon MB, Hauptmann K, Mehran R, Lansky AJ, Baumbach W, Shankar H, Muller R, Feres F et al. Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-eluting stent for treatment of native coronary artery lesions: six-month results of the ETHOS I trial. Catheter Cardiovasc Interv. 2007 Nov 1;70(5):654–60
Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J. 1996 Apr;10(5):615–24.
Dubey, R.K., D.G. Gillespie, B. Imthurn, M. Rosselli et al. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension, 1999. 33(1 Pt 2): 177–82.
Bardelmeijer, H.A., M. Ouwehand, J.H. Beijnen, J.H. Schellens et al. Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl, 2001. 763(1–2): 201–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Sternberg, K. et al. (2009). Development of Drug-Eluting Stents on the Basis of Genistein and Poly(L-lactide). In: Vander Sloten, J., Verdonck, P., Nyssen, M., Haueisen, J. (eds) 4th European Conference of the International Federation for Medical and Biological Engineering. IFMBE Proceedings, vol 22. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-89208-3_535
Download citation
DOI: https://doi.org/10.1007/978-3-540-89208-3_535
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-89207-6
Online ISBN: 978-3-540-89208-3
eBook Packages: EngineeringEngineering (R0)